Career Development Program in Substance Use and Addiction Medicine

项目摘要 培训下一代临床医生和研究人员，以进行变革性的、独立的、患者- 以成瘾为导向的研究将改善成瘾障碍患者的生活，这是公众最高的 健康的重要性，是MGH K12指导的临床科学家发展奖的主要目标 药物滥用和成瘾续期申请。这一更新将支持和加强多学科2-3 一年的强化培训、有指导的研究和专门的职业发展指导计划 多样化、才华横溢的博士后临床医生-致力于患者独立研究事业的科学家- 在成瘾研究实验室提供的丰富培训环境中提供定向成瘾研究 在马萨诸塞州综合医院(MGH)，在MGH，McLean有高级教学培训机会 医院和哈佛医学院(HMS)。这些资源将继续为每个人量身定制 学者的兴趣，以便提供有重点的、集中的培训和指导经验 最大限度地推进每位学者富有成效的、独立的、有影响力的关注成瘾的工作，为他们做好准备 在临床和学术医学、政府和工业方面担任领导职务。职业发展支持 将通过与NIDA K12学者和 导师。医学博士、公共卫生硕士伊登·埃文斯和医学博士南希·里戈蒂将再次成为联合PI的合作伙伴，领导职业生涯 发展项目更新，监督学者的研究和职业发展，学术生产力， 以及在以患者为导向的成瘾研究中走向独立的进展。他们致力于吸引 由经过临床训练的优秀学者组成的多元化团体，在扩大的执行委员会和3- 成功的研究生医学培训项目经验丰富的领导者咨询委员会成员 确定、招聘、留住和促进医学领域代表性不足学者的职业发展 候选人。MPIs是精神病学(Evins博士)和内科(Dr Evins)的HMS教授。 Rigotti)。他们和他们的部门有着悠久的卓有成效的合作历史，并有共同的愿景 扩大多元化、独立的临床成瘾研究队伍。该计划具有很强的制度性 来自MGH领导层的支持。埃文斯博士和里戈蒂博士的共同领导确保了K12学者能够 一个多部门、多学科的培训计划。指导计划包括对学者进行培训1) 获得设计和实施成瘾药物临床研究所需的研究技能；2)准备 科学论文和演示文稿；3)撰写成功的拨款申请；4)负责任地进行研究， 5)开展以患者为中心的成瘾研究的独立事业。他们将通过以下方式实现这一目标 定制的课程工作、个人和小组会议、协作指导以及与 通过MGH临床研究部和哈佛大学提供的丰富的指导资源 催化剂(CTSC)计划。

Project Summary Training the next generation of clinician-investigators to conduct transformational, independent, patient- oriented addiction research that will improve the lives of those with addictive disorders is of the highest public health importance and is the primary goal of this MGH K12 Mentored Clinical Scientist Development Award in Drug Abuse and Addiction renewal application. This renewal will support and strengthen a multidisciplinary 2-3 year program of intensive training, mentored research, and dedicated career development mentorship for diverse, talented, post-doctoral clinician-scientists committed to independent research careers in patient- oriented addiction research provided in the rich training environment of addiction research laboratories based at the Massachusetts General Hospital (MGH), with advanced didactic training opportunities at MGH, McLean Hospital, and Harvard Medical School (HMS). These resources will continue to be individually tailored to each scholar’s interests in order to provide the focused, concentrated training and mentorship experience to optimally advance each Scholar’s productive, independent, impactful addiction-focused work, preparing them for leadership roles in clinical and academic medicine, government and industry. Career development support in the renewal will be bolstered by collaboration with a new national consortium of NIDA K12 scholars and mentors. Eden Evins, MD, MPH, and Nancy Rigotti, MD, will partner again as joint-PIs to lead the career development program renewal, supervising scholars’ research and career development, academic productivity, and progress to independence in patient-oriented addiction research. They are committed to attracting a diverse group of superb clinically-trained scholars, guided by an expanded Executive Committee and a 3- member Advisory Board of experienced leaders of successful postgraduate medical training programs to identify, recruit, retain and foster the career development of underrepresented in medicine (UiM) Scholar candidates. The mPIs are HMS Professors in the Departments of Psychiatry (Dr. Evins) and Medicine (Dr. Rigotti). They and their departments have a long history of productive collaboration and a shared vision for expanding a diverse, independent clinical addiction research workforce. The program has strong institutional support from MGH leadership. Dr. Evins’ and Rigotti’s co-leadership ensures that K12 scholars have access to a multi-departmental program of multi-disciplinary training. The mentoring plan includes training scholars to 1) acquire the research skills needed to design and implement clinical studies in addiction medicine; 2) prepare scientific papers and presentations; 3) write successful grant applications; 4) conduct research responsibly, and 5) launch independent careers in patient-oriented addiction research. They will accomplish this with tailored course work, individual and group meetings, collaborative mentoring, and role modeling integrated with the rich mentoring resources available through the MGH Division of Clinical Research and the Harvard Catalyst (CTSC) Program.